BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Viracta Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:33 pm Sale |
2024-09-30 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-3,833,785 (Position Closed) |
Filing |
| 2023-02-13 5:53 pm Purchase |
2022-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 3,833,785 9.980% |
102,041 (+2.73%) |
Filing |
| 2022-02-14 1:33 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
BIOTECHNOLOGY VALUE FUND L P | 3,731,744 9.900% |
3,731,744 (New Position) |
Filing |